- Home
- SNDX vs LU Comparison
SNDX vs LU Comparison
Compare SNDX & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNDX | LU |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNDX | LU |
|---|---|---|
| Price | $20.14 | $2.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $36.92 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 03-02-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $111,304,000.00 | ★ $4,671,260,668.00 |
| Revenue This Year | $620.14 | N/A |
| Revenue Next Year | $115.42 | $1.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 595.65 | N/A |
| 52 Week Low | $8.58 | $2.25 |
| 52 Week High | $22.73 | $4.57 |
Technical Indicators
Market Signals| Indicator | SNDX | LU |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 46.42 |
| Support Level | $19.57 | $2.56 |
| Resistance Level | $21.49 | $2.75 |
| Average True Range (ATR) | 1.04 | 0.10 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 21.16 | 33.33 |
Price Performance
Historical ComparisonAbout SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.